Osteopontin expression in vascular smooth muscle cells in patients with end-stage renal disease

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 3, 2006, Pages 273-277

  Nakamura, Hironori ^a   Honda, Hirokazu ^a   Inada, Yoshifumi ^b   Kato, Noriyuki ^a   Kato, Kenichi ^a   Kitazawa, Kozo ^a   Sugisaki, Tetsuzo ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANTO ROSAI HOSPITAL   (Japan)

Author keywords

Blood Urea Nitrogen; Osteopontin; Phosphorus; Renal Failure; Vascular Smooth Muscle Cells

Indexed keywords

CALCIUM; COLLAGEN TYPE 1; GLYCEROL 2 PHOSPHATE; MATRIX PROTEIN; OSTEOPONTIN; PHOSPHORUS; UREA;

ADULT; AGED; ARTICLE; BONE MATRIX; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPERPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIAL ARTERY; SMOOTH MUSCLE FIBER; UREA NITROGEN BLOOD LEVEL; UREMIA; VASCULAR SMOOTH MUSCLE;

AGED; AZOTEMIA; BLOOD UREA NITROGEN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOPONTIN; PARATHYROID HORMONE; PHOSPHORUS; RADIAL ARTERY;

EID: 33745547006     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00376.x     Document Type: Article

References (25)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-19.
2. Kawagishi T, Nishizawa Y, Konishi T et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995;48:820-6.
3. Shoji T, Kawagishi T, Emoto M et al. Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 2000;153:257-8.
4. London GM, Marchais SJ, Safar ME et al. Aortic and large artery compliance in end-stage renal failure. Kidney Int 1990;37:137-42.
5. Shoji T, Nishizawa Y, Kawagishi T et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998;9:1277-84.
6. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
7. Asmar R, Benetos A, Topouchian J et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26:485-90.
8. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
9. Shoji T, Emoto M, Shinohara K et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001;12:2117-24.
10. Giachelli CM, Schwartz SM, Liaw L. Molecular and cellular biology of osteopontin. Potential role in cardiovascular disease. Trends Cardiovasc Med 1995;5:88-95.
11. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686-96.
12. Corjay MH, Diamond SM, Schlingmann KL, Gibbs SK, Stoltenborg JK, Racanelli AL. Alphavbeta3, alphavbeta5, and osteopontin are coordinately upregulated at early time points in a rabbit model of neointima formation. J Cell Biochem 1999;75:492-504.
13. O'Brien ER, Garvin MR, Stewart DK et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994;14:1648-56.
14. Takemoto M, Yokote K, Nishimura M et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:624-8.
15. Beck GR Jr, Zerler B, Moran E. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A 2000;97:8352-7.
16. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724-31.
17. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001;37:1267-76.
18. Moe SM, O'Neill KD, Duan D et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002;61:638-47.
19. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973;4:643-6.
20. Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, Morii H. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995;15:2003-9.
21. Watson KE, Parhami F, Shin V, Demer LL. Fibronectin and collagen I matrixes promote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. Arterioscler Thromb Vasc Biol 1998;18:1964-71.
22. Nishizawa Y, Jono S, Ishimura E, Shioi A. Hyperphosphatemia and vascular calcification in end-stage renal disease. J Ren Nutr 2005;15:178-82.
23. Trion A, van der Laarse A. Vascular smooth muscle cells and calcification in atherosclerosis. Am Heart J 2004;147:808-14.
24. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000;275:20197-203.
25. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-17.